

Curriculum Vitae

Personal information **Jakob Paur**

Work experience

1. Employer: AGES Austrian Agency for Health and Food Safety
 - Start date: 022017
 - End date:
 - Position: Preclinical Assessor / Senior Expert
 - Activities: National and EMA Scientific Advice Preclinical assessment of centralized marketing authorization procedures Preclinical assessment of clinical trials
 - Country: Austria
2. Employer: Medical University of Vienna
 - Start date: 032012
 - End date: 032016
 - Position: PhD_Student
 - Activities: planning and conduction of research projects
 - Country: Austria
3. Employer: Max F. Perutz Laboratories (MFPL)
 - Start date: 032009
 - End date: 032010
 - Position: Technical Assisant
 - Activities:
 - Country: Austria

Education and training

1. Subject: University of Vienna, Institute of Cancer Research
 - Start date: 032012
 - End date: 082016
 - Qualification: PhD
 - Organisation: PhD_Thesis: The role of fibroblast growth factor receptors 3 and 4 and the high affinity FGFR3 ligand FGF9 in the progression of hepatocellular carcinoma
 - Country: Austria
2. Subject: Medical University of Vienna
 - Start date: 032012
 - End date: 012016
 - Qualification: Master of Science (Toxicology)
 - Organisation: Postgraduate University Course in Toxicology (Chemical Safety)
 - Country: Austria
3. Subject: University of Vienna, Center of Translational Research
 - Start date: 032007
 - End date: 112011
 - Qualification: Mag.rer.nat.
 - Organisation: Diploma Studies of Microbiology and Genetics with focus on Molecular Pathology Diploma_Thesis: Mitochondria in cancer and degenerative diseases
 - Country: Austria
4. Subject:
 - Start date: 112016
 - End date: 112016
 - Qualification: Seminar: Preparation for the Certification as Junior Project Manager (IPMA®)
 - Organisation:
 - Country: Austria

Additional information

Publications

van der Laan JW, Andersson M, Beken S, Bonelli M, Brendler-Schwaab S, Kane R, Pasanen M, Ponzano S, Paur J, Siezen C, Soleng A, Whomsley R. EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals. Br J Clin Pharmacol. 2023 Jun 2. doi: 10.1111/bcp.15790. Epub ahead of print. PMID: 37265032.

Paur J, Valler M, Sieneel R, Taxauer K, Holzmann K, Marian B, et al. Interaction of FGF9 with FGFR3_IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma. Liver Int. 2020 May 7. doi: 10.1111/liv.14505

Paur J, Nika L, Maier C, Moscu_Gregor A, Kostka J, Huber D, et al. Fibroblast growth factor receptor 3 isoforms: novel therapeutic targets for hepatocellular carcinoma? Hepatology 2015. doi:10.1002/hep.28023.

Wilfinger N, Austin S, Scheiber_Mojdekhar B, Berger W, Reipert S, Pranschberger M, Paur J, et al. Novel p53_dependent anticancer strategy by targeting iron signaling and BNIP3L_induced mitophagy. Oncotarget 2015; doi: 10.18632/oncotarget.6233.

Gaughhofer C, Paur J, Schrottmaier WC, Wingelhofer B, Huber D, Naegelen I, et al. Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. Carcinogenesis 2014;35(10):2331_8.

Heinze C, Erdem Z, Paur J, Grasl-Kraupp B, Holzmann K, Grusch M, et al. Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr Pharm Des. 2014;20(17):2881_98.

Projects

Memberships

ASTOX _ Austrian Society of Toxicology

EUROPEAN Registered Toxicologist (ERT)

Other Relevant Information